CN113633657A - Pharmaceutical composition for improving anti-fatigue, anti-hypoxia, heat-resistant and cold-resistant abilities of organism and application thereof - Google Patents
Pharmaceutical composition for improving anti-fatigue, anti-hypoxia, heat-resistant and cold-resistant abilities of organism and application thereof Download PDFInfo
- Publication number
- CN113633657A CN113633657A CN202110500385.8A CN202110500385A CN113633657A CN 113633657 A CN113633657 A CN 113633657A CN 202110500385 A CN202110500385 A CN 202110500385A CN 113633657 A CN113633657 A CN 113633657A
- Authority
- CN
- China
- Prior art keywords
- ginsenoside
- pharmaceutical composition
- fatigue
- polysaccharide
- resistant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 27
- 206010021143 Hypoxia Diseases 0.000 title claims abstract description 14
- 230000002929 anti-fatigue Effects 0.000 title claims abstract description 13
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 claims abstract description 32
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 claims abstract description 32
- CKUVNOCSBYYHIS-LGYUXIIVSA-N 20(R)-Ginsenoside Rh2 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CC/C=C(\C)/C)C)CC4)CC2)CC1 CKUVNOCSBYYHIS-LGYUXIIVSA-N 0.000 claims abstract description 32
- 239000008518 lycium barbarum polysaccharide Substances 0.000 claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 25
- 150000004676 glycans Chemical class 0.000 claims abstract description 17
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 17
- 239000005017 polysaccharide Substances 0.000 claims abstract description 17
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 15
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 15
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 230000036541 health Effects 0.000 claims abstract description 7
- 241001465754 Metazoa Species 0.000 claims description 13
- 235000013305 food Nutrition 0.000 claims description 8
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 7
- 230000007954 hypoxia Effects 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 241000282414 Homo sapiens Species 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 241000282693 Cercopithecidae Species 0.000 claims description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 2
- 241000009328 Perro Species 0.000 claims description 2
- 241000700159 Rattus Species 0.000 claims description 2
- 241000282898 Sus scrofa Species 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000006870 function Effects 0.000 abstract description 7
- 239000000463 material Substances 0.000 abstract description 5
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- 206010002660 Anoxia Diseases 0.000 abstract description 3
- 241000976983 Anoxia Species 0.000 abstract description 3
- 235000017784 Mespilus germanica Nutrition 0.000 abstract description 3
- 244000182216 Mimusops elengi Species 0.000 abstract description 3
- 235000000560 Mimusops elengi Nutrition 0.000 abstract description 3
- 235000007837 Vangueria infausta Nutrition 0.000 abstract description 3
- 230000007953 anoxia Effects 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 230000003285 pharmacodynamic effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 20
- 206010016256 fatigue Diseases 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 229940089161 ginsenoside Drugs 0.000 description 9
- 229930182494 ginsenoside Natural products 0.000 description 9
- 241000208340 Araliaceae Species 0.000 description 7
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 7
- 235000003140 Panax quinquefolius Nutrition 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 235000008434 ginseng Nutrition 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000009182 swimming Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 229920003081 Povidone K 30 Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 241000234653 Cyperus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- HUAUNKAZQWMVFY-UHFFFAOYSA-M sodium;oxocalcium;hydroxide Chemical compound [OH-].[Na+].[Ca]=O HUAUNKAZQWMVFY-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/50—Feeding-stuffs specially adapted for particular animals for rodents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a pharmaceutical composition for improving the anti-fatigue, anti-hypoxia, heat-resistant and cold-resistant abilities of an organism and an application thereof, wherein the pharmaceutical composition is composed of ginsenoside Rh2 and lycium barbarum polysaccharide, and the weight ratio of the ginsenoside Rh2 to the lycium barbarum polysaccharide is 1: 30-1: 1500. Pharmacodynamic researches show that the composition of the ginsenoside Rh2 and the wolfberry (medlar) polysaccharide in a certain proportion combination range has obvious functions of resisting fatigue and improving anoxia, cold resistance and heat resistance, and has a synergistic effect compared with the ginsenoside Rh2 or the wolfberry polysaccharide alone. The composition of the invention can be applied to medicine and health care products by matching with proper medicinal and edible auxiliary materials.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to application of a composition of ginsenoside Rh2 and wolfberry (wolfberry) polysaccharide in resisting fatigue and improving the functions of hypoxia tolerance, cold resistance and heat resistance. Compared with ginsenoside Rh2 and lycium barbarum polysaccharide, the ginsenoside Rh2 and lycium barbarum polysaccharide have synergistic effect.
Background
People inevitably encounter the phenomenon of reduced working ability in daily life and production, which we call fatigue, and in the 5 th international meeting of sports biochemistry in 1982, sports fatigue is defined as: "the Physiological processes of the body cannot maintain their function at a specific level and/or cannot maintain their predetermined exercise intensity" [ Allen DG, Lamb GD, Westerblank H.Skelet Muscle Fatigue: Cellular mechanics, Physiological Reviews,2008, 88: 287-. With the increasingly fierce social competition, the pace of life is accelerated, the working pressure is increased, and the incidence of fatigue is on an increasing trend. Fatigue, while not directly threatening human life as cancer, cardiovascular disease, can severely impact human quality of life. Long-term fatigue can lead the body to be in a sub-healthy state, which is mainly manifested by fatigue, hypoactivity, reduced immunity, etc. [ Yu-xing Yang, You-Qin Liu, Man Li et al, Development and Evaluation of a questingnaire for Measuring Subotial Health Status in Urban Chinese, J epidemic.2009; 19:333-341.]. At present, most of methods for relieving fatigue adjust the organism through sleeping and recuperation, and on the other hand, the adjustment of external substances is relied on to improve the body function. However, there is currently a lack of effective drugs and methods that provide most of the fatigue without relief by passive psychological adjustment or administration of some sort of excitement-enhancing drug. Modern western medicine lacks an effective treatment means for the sub-health state, and traditional Chinese medicine accumulates abundant experience in the aspect and shows unique advantages.
Ginseng is a good medicine for nourishing and strengthening from ancient times, and modern researches also show that ginseng plays a good role in resisting fatigue, but the active ingredients of ginseng are unknown. Patent 200610017063.3 discloses the anti-fatigue effect of a composition of ginseng, coffee, tea. Patent 200610131959.4 discloses a new use of ginsenoside Rh2 in anti-fatigue, and the drug has little adverse reaction and is an ideal anti-fatigue drug.
The fructus Lycii is dry mature fruit of fructus Lycii of Solanaceae, and is traditional Chinese medicine, and has effects of nourishing and strengthening body, replenishing vital essence, dispelling pathogenic wind, tonifying yang, strengthening tendons and bones, etc., and modern scientific research proves that fructus Lycii effective component is fructus Lycii polysaccharide, and has effects of reducing blood sugar, reducing blood lipid, improving immunity, resisting oxidation, and relieving fatigue. The Chinese wolfberry recorded in the dietetic herbal has the functions of strengthening muscle and tendon, resisting fatigue, dispelling wind, tonifying bones and muscles, benefiting people and removing consumptive disease. The polysaccharide contained in the polysaccharide is a natural plant polysaccharide, has rich biological activity and no toxic or side effect [ Teng Jun, Yuan Jia, Cyperus, medlar chemical component and pharmacological action correlation summary. strait pharmacology, 2014,26:36-37 ], and has wide prospects in clinical application and health food development.
At present, the report of the combined use of the ginsenoside Rh2 and the wolfberry (medlar) polysaccharide in the aspects of improving the fatigue resistance, oxygen deficiency resistance, heat resistance and cold resistance of the organism is not seen.
Disclosure of Invention
The invention aims to provide a pharmaceutical composition aiming at the defects in the prior art.
The second purpose of the invention is to provide the application of the pharmaceutical composition.
In order to achieve the purpose, the invention adopts the technical scheme that:
a pharmaceutical composition comprises ginsenoside Rh2 and lycium barbarum polysaccharide, wherein the weight ratio of the ginsenoside Rh2 to the lycium barbarum polysaccharide is 1: 30-1: 1500.
Further, the weight ratio of the ginsenoside Rh2 to the lycium barbarum polysaccharide is 1: 30-1: 40.
Further, the weight ratio of the ginsenoside Rh2 to the lycium barbarum polysaccharide is 1: 40.
In order to achieve the second object, the invention adopts the technical scheme that:
the application of any one of the pharmaceutical compositions in preparing anti-fatigue medicines, foods or health products.
Furthermore, the medicine is added with pharmaceutically acceptable matrix auxiliary materials according to the needs to be prepared into any pharmaceutical dosage form.
Furthermore, the dosage form of the medicine is capsule, granule, tablet, oral liquid or mixture.
Further, the pharmaceutically acceptable base excipients include, but are not limited to: sodium carboxymethylcellulose, mannitol, sorbitol, sodium metabisulfite, sodium bisulfite, sodium thiosulfate, cysteine hydrochloride, thioglycolic acid, methionine, vitamin C, EDTA disodium, calcium sodium EDTA, monovalent alkali metal carbonates, acetates, phosphates or aqueous solutions thereof, hydrochloric acid, acetic acid, sulfuric acid, phosphoric acid, amino acids, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivatives, cellulose and derivatives thereof, alginates, gelatin, polyvinylpyrrolidone, glycerol, Tween 80, agar, calcium carbonate, calcium bicarbonate, surfactants, polyethylene glycol, cyclodextrin, beta-cyclodextrin, phospholipid materials, kaolin, talc, calcium stearate, magnesium stearate.
The application of the pharmaceutical composition in preparing a medicament, food or health-care product for improving the hypoxia tolerance of an animal individual.
The application of the pharmaceutical composition in preparing a medicament, food or health-care product for improving the cold resistance of an animal individual.
The application of the pharmaceutical composition in preparing a medicine, food or health-care product for improving the heat resistance of an animal individual.
Further, the animal is a mammal.
Further, the mammal is selected from human, rat, mouse, monkey, dog, rabbit or pig.
The invention has the advantages that:
1. the pharmaceutical composition is screened by a large number of comparative tests by the inventor, wherein the ginsenoside Rh2 has good anti-fatigue activity, but has low content in medicinal materials, is expensive and is not suitable for being used in large dose, and the anti-fatigue effect of the lycium barbarum polysaccharide is not obvious. The invention obviously reduces the use proportion of the ginseng soap Rh2, reduces the medicine cost and obviously enhances the anti-fatigue activity of the medicine through the synergistic effect of the ginseng soap Rh2 and the lycium barbarum polysaccharide.
2. The pharmaceutical composition can improve the anoxia resistance, cold resistance and heat resistance of animal individuals, and the ginsenoside Rh2 and the lycium barbarum polysaccharide show synergistic effect. The method has important significance for improving the survival capability of animal individuals under extreme climatic conditions.
Detailed Description
The invention will be further illustrated with reference to specific embodiments. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. Furthermore, it should be understood that various changes and modifications can be made by those skilled in the art after reading the disclosure of the present invention, and equivalents fall within the scope of the appended claims.
The term "acceptable" as used herein means that a prescribed component or active ingredient does not unduly adversely affect the health of the general therapeutic target.
The term "pharmaceutically acceptable" as used herein refers to a substance, such as a carrier or diluent, which does not diminish the biological activity or properties of the compound and which is relatively non-toxic, e.g., a substance that is administered to an individual without causing unwanted biological effects or interacting in a deleterious manner with any of the components it contains.
EXAMPLE 1 pharmaceutical composition (I) of the invention
Weighing 21 parts of ginsenoside Rh and 10 parts of lycium barbarum polysaccharide according to the weight part ratio, and uniformly mixing.
Example 2 pharmaceutical composition of the invention
Weighing and uniformly mixing 21 parts of ginsenoside Rh and 20 parts of lycium barbarum polysaccharide in parts by weight.
Example 3 pharmaceutical composition of the invention
Weighing and uniformly mixing 21 parts of ginsenoside Rh and 40 parts of lycium barbarum polysaccharide in parts by weight.
Example 4 pharmaceutical composition of the Invention (IV)
Weighing 22 parts of ginsenoside Rh and 10 parts of lycium barbarum polysaccharide according to the weight part ratio, and uniformly mixing.
EXAMPLE 5 pharmaceutical composition of the invention (V)
Weighing and uniformly mixing 22 parts of ginsenoside Rh and 20 parts of lycium barbarum polysaccharide in parts by weight.
Example 6 pharmaceutical composition of the invention (VI)
Weighing and uniformly mixing 22 parts of ginsenoside Rh and 40 parts of lycium barbarum polysaccharide in parts by weight.
Example 7 preparation of a Capsule of ginsenoside Rh2 and Lycium barbarum polysaccharides of the invention
Ginsenoside Rh 28 g, wolfberry polysaccharide 1600 g, lactose and sodium carboxymethylcellulose are added, mixed uniformly, sieved by a 80-mesh sieve, added with a proper amount of 70% ethanol solution of 5% povidone K30 to prepare soft materials, sieved by a 40-mesh sieve, granulated and filled into capsules to obtain capsules.
EXAMPLE 8 preparation of tablets of ginsenoside Rh2 and Lycium barbarum polysaccharides of the present invention
Ginsenoside Rh 28 g, wolfberry polysaccharide 1600 g, lactose and sodium carboxymethylcellulose are added, mixed uniformly, sieved by a 80-mesh sieve, added with a proper amount of 70% ethanol solution of 5% povidone K30 to prepare a soft material, sieved by a 20-mesh sieve, added with a proper amount of magnesium stearate, mixed uniformly, and tableted to obtain tablets.
Example 9 preparation of an oral liquid of ginsenoside Rh2 and Lycium barbarum polysaccharides of the present invention
Tween-80, ginsenoside Rh 28 g, and Lycium barbarum polysaccharides 1600 g, grinding to obtain colostrum, and adding water to 4000ml to obtain oral solution.
Example 10 animal experiments with pharmaceutical compositions of the invention
1. Material
1.1 Experimental animals
Clean-grade mice, 18-20g, were purchased from the animal testing center of second university of military medical science. License number: SCXK (Shanghai) 2013 and 0003.
1.2 drugs
Ginsenoside Rh2, purchased from pharmaceutical science and technology Limited, with a content of 99% or more.
The lycium barbarum polysaccharide is purchased from the pharmaceutical technology limited company, and the content is more than or equal to 35%.
2. Method of producing a composite material
2.1 animal grouping and administration
The weight of each group was randomly divided into 40 individuals. Negative control: and (5) solvent control. Administration dose: ginsenoside Rh2, 1mg/Kg, 2mg/Kg (R1, R2); wolfberry polysaccharide: 10mg/Kg, 20mg/Kg, 40mg/Kg (LBP-L, LBP-M, LBP-H). Ginsenoside Rh2+ lycium barbarum polysaccharide: 1mg/Kg +10mg/Kg, 1mg/Kg +20mg/Kg, 1mg/Kg +40mg/Kg (R1+ LBP-L, R1+ LBP-M, R1+ LBP-H); ginsenoside Rh2+ lycium barbarum polysaccharide: 2mg/Kg +10mg/Kg, 2mg/Kg +20mg/Kg, 2mg/Kg +40mg/Kg (R2+ LBP-L, R2+ LBP-M, R2+ LBP-H).
Preparing the medicine: weighing a certain amount of ginsenoside Rh2, adding a small amount of 0.3% CMC-Na, grinding to obtain suspension, and diluting with CMC-Na to desired concentration. Adding lycium barbarum polysaccharide into the ginsenoside Rh2 suspension to prepare a composition with a corresponding concentration. The lycium barbarum polysaccharide is prepared into solutions of 1, 2 and 4g/L respectively. The administration method comprises the following steps: the administration is carried out by intragastric administration for 15 days by intragastric administration for 1 time each day.
2.2 Normal pressure anoxia test
And taking 10 mice out of each group, performing intragastric administration for 1 hour at the end of 15 days, putting into a 300mL wide-mouth bottle containing 10g of soda lime, coating vaseline on the bottle cap, sealing to prevent air leakage, and recording the survival time of the mice.
2.3 weight bearing swimming test
Taking out 10 mice from each group, after 1h of last intragastric administration, applying 5% of lead skin of the tail of the mouse, placing the mice in a glass swimming box with the water depth of 30cm for swimming, keeping the water temperature at (25 +/-1) DEG C, and recording the swimming survival time of the mice.
2.4 Cold resistance test
Taking out 10 mice from each group, performing last intragastric administration for 1h, respectively loading into 4 iron wire cages, placing in a refrigerator at-20 deg.C, and recording the death number of each group of mice by taking 20 mice out of 4 groups.
2.5 Heat resistance test
Taking out 10 mice from each group, after 1h of last gastric lavage, respectively putting the mice into 4 iron wire cages, putting the cages into a 50 ℃ oven, and recording the death number of each group of mice by taking 30 mice died in the total number of 4 groups of mice as a boundary.
2.6 statistical treatment
All experimental data were analyzed by SPSS 11.0 statistical software, and the data were measured as mean + -SD
As shown, the comparison among groups is performed by using a t test, and the difference of P <0.05 is statistically significant.
3. Results
TABLE 1 Effect of different compositions on forced swim mice and hypoxia-resistant mice
Note, comparison to blank control: p < 0.05; p <0.01
TABLE 2 Effect of different compositions on Cold and Heat tolerance in mice
Note, comparison to blank control: p < 0.05; p <0.01
The results of the experiment are shown in tables 1 and 2. The results show that: the composition combined by different dosages can prolong the weight-bearing swimming time of the mouse, prolong the hypoxia tolerance time of the mouse and increase the survival rate of the mouse under the high cold and high heat environments, and has more obvious statistical significance (P <0.05 or P <0.01) compared with a blank control group.
4. Conclusion
The ginsenoside Rh2 and wolfberry polysaccharide composition (ginseng and wolfberry) has the functions of obviously prolonging the hypoxia tolerance time of mice and the load swimming time of the mice, and the survival rate of the mice in cold and high-heat resistant environments, namely, the composition shows obvious anti-fatigue effect and the function of improving the adaptability of individuals to the extreme environment. A comparison test is designed in the early stage of an experiment, under the same administration dosage and the same experiment conditions, the improvement effect of the ginsenoside Rh2 and lycium barbarum polysaccharide combination on the anti-fatigue, anti-hypoxia, cold-resistant and heat-resistant capabilities of a mouse is obviously higher than that of the ginsenoside Rh2 or the lycium barbarum polysaccharide alone, and the remarkable synergistic effect of the ginsenoside Rh2 and lycium barbarum polysaccharide combination is proved.
The above description is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, several modifications and additions can be made without departing from the method of the present invention, and these modifications and additions should also be regarded as the protection scope of the present invention.
Claims (10)
1. The pharmaceutical composition is characterized by consisting of ginsenoside Rh2 and lycium barbarum polysaccharide, wherein the weight ratio of the ginsenoside Rh2 to the lycium barbarum polysaccharide is 1: 30-1: 1500.
2. The pharmaceutical composition according to claim 1, wherein the weight ratio of the ginsenoside Rh2 to the lycium barbarum polysaccharide is 1: 30-1: 40.
3. The pharmaceutical composition of claim 1, wherein the weight ratio of ginsenoside Rh2 to wolfberry polysaccharide is 1: 40.
4. The use of the pharmaceutical composition of claim 1 for the preparation of an anti-fatigue medicament, food or health product.
5. The use according to claim 4, wherein the medicament is in the form of a capsule, granule, tablet, oral liquid or mixture.
6. Use of the pharmaceutical composition of claim 1 in the manufacture of a medicament, food or health product for enhancing the hypoxia tolerance of an animal subject.
7. Use of the pharmaceutical composition of claim 1 in the manufacture of a medicament, food or health product for improving cold resistance in an animal subject.
8. Use of the pharmaceutical composition of claim 1 in the manufacture of a medicament, food or health product for increasing the heat resistance of an animal subject.
9. The use of any one of claims 6 to 8, wherein the animal is a mammal.
10. The use according to claim 9, wherein the mammal is selected from the group consisting of human, rat, mouse, monkey, dog, rabbit and pig.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110500385.8A CN113633657B (en) | 2021-05-08 | 2021-05-08 | Pharmaceutical composition for improving body anti-fatigue, hypoxia-resistant, heat-resistant and cold-resistant capacities and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110500385.8A CN113633657B (en) | 2021-05-08 | 2021-05-08 | Pharmaceutical composition for improving body anti-fatigue, hypoxia-resistant, heat-resistant and cold-resistant capacities and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113633657A true CN113633657A (en) | 2021-11-12 |
| CN113633657B CN113633657B (en) | 2024-03-01 |
Family
ID=78415777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110500385.8A Active CN113633657B (en) | 2021-05-08 | 2021-05-08 | Pharmaceutical composition for improving body anti-fatigue, hypoxia-resistant, heat-resistant and cold-resistant capacities and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113633657B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116115696A (en) * | 2023-04-07 | 2023-05-16 | 中国人民解放军空军军医大学 | Traditional Chinese medicine composition for improving cold Xi Fu capacity of organism and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101502316A (en) * | 2009-03-11 | 2009-08-12 | 中国科学院武汉植物园 | Method for extracting medlar polysaccharide |
| CN101612159A (en) * | 2008-06-23 | 2009-12-30 | 上海药谷药业有限公司 | The application of chemical compound 20 (S)-ginsenoside Rh2 in the preparation anti-fatigue medicament |
| CN101890040A (en) * | 2010-07-27 | 2010-11-24 | 上海中药创新研究中心 | Composition with anti-fatigue effect and application thereof |
| CN110237153A (en) * | 2019-07-29 | 2019-09-17 | 北京本草方源药业集团有限公司 | A kind of mixture pellets and preparation method thereof |
-
2021
- 2021-05-08 CN CN202110500385.8A patent/CN113633657B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101612159A (en) * | 2008-06-23 | 2009-12-30 | 上海药谷药业有限公司 | The application of chemical compound 20 (S)-ginsenoside Rh2 in the preparation anti-fatigue medicament |
| CN101502316A (en) * | 2009-03-11 | 2009-08-12 | 中国科学院武汉植物园 | Method for extracting medlar polysaccharide |
| CN101890040A (en) * | 2010-07-27 | 2010-11-24 | 上海中药创新研究中心 | Composition with anti-fatigue effect and application thereof |
| CN110237153A (en) * | 2019-07-29 | 2019-09-17 | 北京本草方源药业集团有限公司 | A kind of mixture pellets and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 盛伟，等: "枸杞多糖对小鼠耐缺氧及抗疲劳能力的影响", 《新乡医学院学报》, vol. 28, no. 3, pages 298 - 300 * |
| 詹益兴，主编: "《绿色精细化工——天然产品制造法（第1集）》", 科学技术文献出版社, pages: 207 - 208 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116115696A (en) * | 2023-04-07 | 2023-05-16 | 中国人民解放军空军军医大学 | Traditional Chinese medicine composition for improving cold Xi Fu capacity of organism and preparation method and application thereof |
| CN116115696B (en) * | 2023-04-07 | 2023-12-12 | 中国人民解放军空军军医大学 | Traditional Chinese medicine composition for improving cold Xi Fu capacity of organism and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113633657B (en) | 2024-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101890040B (en) | Composition with anti-fatigue effect and application thereof | |
| CN102018832B (en) | Weight-reducing composition and preparation method thereof | |
| US20110118359A1 (en) | Ampk activating agent | |
| CN111035649A (en) | NMN + GLP compound nutritional supplement and preparation method and application thereof | |
| CN103355655A (en) | Composition with alimentary anemia improving function and preparation method of composition | |
| CN108065286A (en) | A kind of chewable tablets containing acerola concentrate powder, VC and taurine and preparation method thereof | |
| CN113633657B (en) | Pharmaceutical composition for improving body anti-fatigue, hypoxia-resistant, heat-resistant and cold-resistant capacities and application thereof | |
| CN117018125B (en) | Anti-fatigue pharmaceutical composition | |
| CN101496828B (en) | Use of total saponin extract of fenugreek | |
| CN111110696A (en) | Composition, preparation and application | |
| CN105250989A (en) | Donkey-hide glue small peptide composition for resisting fatigue | |
| CN105533596A (en) | Propolis, radix salviae miltiorrhizae and ginkgo leaf capsules and preparation method thereof | |
| WO2021213502A1 (en) | Sleep-improving pharmaceutical composition containing rare ginsenosides rg6 and f4 | |
| CN101897717B (en) | Chinese medicinal composition for treating diabetes and application | |
| CN112075633A (en) | Natural extract and dietary fiber compounded weight-losing composition | |
| CN1287808C (en) | Ginkgo leaf extract composition | |
| CN109432082B (en) | Pharmaceutical composition for preventing and treating chemical liver injury | |
| CN116585379B (en) | Traditional Chinese medicine composition, method and application for preventing and treating hyperuricemia and gout | |
| CN108669530A (en) | A kind of Hericium erinaceus composition, tablet and preparation method conducive to stomach health | |
| CN110404029B (en) | Composition with blood sugar reducing effect and preparation method and application thereof | |
| CN101491584A (en) | Combination with blood sugar reducing function and preparation method thereof | |
| CN100551357C (en) | The application of prepared from coriolus versicolor mycelium in preparation resisting fatigue medicament | |
| CN106108016A (en) | A kind of health food for relieving physical fatigue and preparation method thereof | |
| CN117838721A (en) | Composition with synergistic long-acting blood glucose level regulation function and preparation method thereof | |
| CN117883520A (en) | Ginseng Mulberry Huang Erqing Quercetin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |